Psilocybin can restore mGluR2 levels in the prefrontal cortex, and this leads to a reduced risk of relapse for those with alcohol use disorder.
Microdosing psychedelics like LSD and psilocybin alleviates symptoms of depression and anxiety while improving feelings of wellbeing.
A growing body of evidence suggests psychedelics including psilocybin and LSD show promise in providing lasting relief from symptoms for those suffering some mental health disorders. Researchers found DOI, a similar drug to LSD, reduced negative behavioral responses following fear triggers in mouse models of anxiety.
Drums, dance, sleep deprivation, and drugs, referred to as the 4D's in the rave scene was associated with personal transformation for those who considered a rave to be an awe-inspiring event. The more a person felt personally transformed by the experience, the more bonded to the fellow ravers they felt. This phenomenon may explain the long-standing popularity of the rave scene.
Altered behaviors associated with LSD may be caused by a reduction in the normal communication between the hippocampus and visual cortex.
From treating depression and other mental health disorders, to helping relieve chronic pain, researchers discuss the advantages and implications of psychedelic treatments.
One dose of psilocybin, the psychoactive compound found in magic mushrooms, increases dendritic spine density within 24 hours. The neurobiological changes lasted for a month following psilocybin exposure. Additionally, mice subjected to stress showed behavioral improvements and increased neurotransmitter activity after psilocybin exposure.
A single dose of tabernanthalog (TBG), a non-hallucinogenic psychedelic analog, corrects stress-induced behavioral deficits, including anxiety and cognitive inflexibility, in mouse models. Additionally, the compound promoted neurogenesis and restores neural circuits in brain areas damaged by stress.
PsychLight, a newly developed genetically encoded fluorescent sensor, helped researchers identify a psychedelic compound that acts on beneficial neural pathways to treat psychiatric disorders without the hallucinogenic effect.
Psilocybin, the psychoactive compound found in magic mushrooms, is as effective at treating depression as conventional SSRI antidepressants. Researchers report, that although not significantly significant, early findings reveal those treated with psilocybin experienced more rapid and greater reductions in depression symptoms than those treated with SSRIs.
A mouse study refutes the common belief that psilocybin's ability to produce an anti-depressant effect is attributed to the psychedelic experience it creates. Blocking the psychedelic effect did not affect psilocybin's anti-depressant effects.
As interest in using psychedelics to treat a range of mental health disorders grows, researchers consider the impact and therapeutic benefits of using psychedelics to help alleviate symptoms of depression.
